Delving into the Latest Updates on Anti-thymocyte Globulin (Rabbit) with Synapse

Overview

Basic Info

Drug Type

Immunoglobulin

Synonyms

Anti-human thymocyteimmunoglobulin, Rabbit, Thymoglobulin, Thymoglobuline

+ [2]

Target-

Action

inhibitors

Mechanism

Thymocyte inhibitors

Therapeutic Areas

Immune System DiseasesInfectious DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Graft RejectionBacterial InfectionsGraft vs Host Disease+ [5]

Inactive Indication

Acute Graft Versus Host DiseaseAcute Myeloid LeukemiaAcute rejection of renal transplant+ [20]

Originator Organization

Genzyme Corp.

Active Organization

Sanofi KK

Genzyme Corp.Sanofi-Aventis Australia Pty Ltd.

+ [1]

Inactive Organization

Sanofi

Drug Highest PhaseApproved

First Approval Date

South Korea (19 Jan 1993),

Anemia, AplasticCardiac transplant rejectionRenal transplant rejection

RegulationOrphan Drug (United States)

Login to view timeline

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, we observed that Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse.
In this phase III randomised study, we propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.

Start Date01 Nov 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT05743400

/ RecruitingPhase 4IIT

Thymoglobulin® Pharmacokinetics for Graft-versus Host Disease in Children and Adults Undergoing Hematopoietic Stem Cell Transplantation

Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell transplantations (HSCT), with a delicate balance between prevention of GvHD and the promotion of immune reconstitution. Thymoglobulin is known as a drug with high pharmacokinetic (PK) variability. This variability influences drug exposure, which in turn determines the drug response of pharmacodynamics (PD). In order to maintain efficacy while reducing adverse effects of drugs across the entire age range, identification of the PK/PD relationships and the effect of growth and maturation on the different PK and PD parameters involved are crucial.
The investigators hypothesise that a better knowledge of Thymoglobulin PK and its covariates would help to individualise dosage regimen and would improve clinical outcomes, such as GvHD and immune reconstitution.
The investigators aim to build a population PK model of Thymoglobulin in order to study PK variability and its covariates. This model will help in optimizing dosage regimen in an individually way.

Start Date25 Sep 2023

Sponsor / Collaborator

Hospices Civils de Lyon

100 Clinical Results associated with Anti-thymocyte Globulin (Rabbit)

Login to view more data

100 Translational Medicine associated with Anti-thymocyte Globulin (Rabbit)

Login to view more data

100 Patents (Medical) associated with Anti-thymocyte Globulin (Rabbit)

Login to view more data

4,927

Literatures (Medical) associated with Anti-thymocyte Globulin (Rabbit)

01 Dec 2025·Blood Research

Post-transplant cyclophosphamide plus anti-thymocyte globulin decreased serum IL-6 levels when compared with post-transplant cyclophosphamide alone after haploidentical hematopoietic stem cell transplantation

Article

Author: Kim, Chul Hee ; Ryu, Hyewon ; Heo, Bu Yeon ; Seo, Wonhyoung ; Song, Ik-Chan ; Choi, Suyoung ; Jo, Deog-Yeon ; Lee, Sang-Woo ; Kang, Sora ; Lee, Seul Bi ; Pham, Thi Thuy Duong ; Lee, Hyo-Jin ; Lee, Myung-Won ; Eun, Hyuk Soo ; Koh, Jeong Suk ; Yun, Hwan-Jung

AbstractBackgroundPost-transplantation cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) are common prophylactic strategies for graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Interleukin (IL)-6 is a surrogate marker for cytokine release syndrome (CRS) and acute GVHD.MethodThe clinical outcomes and complications of haplo-HSCT with PTCy plus ATG versus PTCy monotherapy were compared according to serum IL-6 levels at Chungnam National University Hospital (Daejeon, South Korea) from January 2019 to February 2023.ResultsForty patients who underwent haplo-HSCT were analyzed. A significant difference in IL-6 levels was observed between the PTCy plus ATG and PTCy alone groups (7.47 ± 10.55 vs. 117.65 ± 127.67; p = 0.003). More patients in the PTCy plus ATG group had a CRS grade of 0 than in the PTCy alone group (p < 0.001). Serum IL-6 levels were associated with grades II–IV acute GVHD (r = 0.547, p < 0.001). The cumulative incidence (CI) of grades II–IV acute GVHD was significantly higher in the PTCy alone group (67.9% vs. 4.8%; p < 0.001). No significant difference in the CI for chronic GVHD was detected between the PTCy plus ATG and PTCy alone groups (72.1% vs. 82.0%; p = 0.730). The CI of 1-year non-relapse mortality was significantly higher in the PTCy alone group than in the PTCy plus ATG group (42.2% vs. 15.9%; p = 0.022). The 1-year overall survival (OS) was significantly better in the PTCy plus ATG group (75.9% vs. 35.3%; p = 0.011). The 1-year GVHD-free, relapse-free survival rate was 29.4% in the PTCy alone group and 54.0% in the PTCy plus ATG group (p = 0.038).ConclusionSerum IL-6 levels were higher in the PTCy alone group than in the PTCy plus ATG group. The addition of ATG before stem cell infusion affected IL-6 levels and reduced the incidences of CRS and grade II–IV acute GVHD in haplo-HSCT patients. This study suggests that PTCy plus ATG as GVHD prophylaxis in haplo-HSCT is beneficial in terms of clinical outcomes and complications of HSCT.

01 Mar 2025·Transplantation Proceedings

Trends in the Perioperative Practices for Immunological Assessment and Immunosuppression Strategies for Patients Undergoing Intestinal Transplantation at American Transplant Centers

Article

Author: Lyer, Kishore ; Horslen, Simon ; Mangus, Richard S ; Farmer, Douglas G ; Schiano, Thomas D ; Mavis, Alisha M ; Abusuliman, Mohammed ; Abusuliman, Amr ; Langnas, Alan N ; Sulejmani, Nimisha ; Summers, Bryant B ; Matsumoto, Cal S ; Sudan, Debra L ; Jafri, Syed-Mohammed ; Nagai, Shunji ; O'Leary, Jacqueline ; Segovia, Maria Cristina ; Beduschi, Thiago ; Mazariegos, George V ; Boike, Justin

BACKGROUNDIntestinal transplantation (IT) is a complex procedure that requires nuanced immunosuppressive strategies to optimize patient outcomes. Despite advancements, significant variability remains in immunosuppressive protocols across transplant centers due to a lack of consensus on the optimal approaches for induction, maintenance, and clinical testing. This variability complicates standardization and identification of best practices for IT recipients.METHODSA descriptive survey study was conducted to characterize immunosuppressive and testing strategies in IT at major transplant centers in the United States. Ten centers known to have performed over 10 ITs since 2015 were selected from the Scientific Registry of Transplant Recipients database. A 22-question survey was distributed to surgical directors, collecting data on pre-, peri-, and post-transplant immunological testing, desensitization strategies, immunosuppressive regimens, and management of antibody-mediated rejection (AMR) and acute cellular rejection (ACR).RESULTSNine centers (90%) responded. All centers conducted pretransplant human leukocyte antigen (HLA) and donor-specific antibody (DSA) testing, with varying frequencies and methodologies. Desensitization was reported by 44% of centers for isolated IT and by 22% for multivisceral transplants. Induction therapy predominantly involved antithymocyte globulin (89%) and rituximab (44%). Tacrolimus was universally used for maintenance, with varying trough level targets across centers. Post-transplant DSA testing was performed by all centers, and protocol-driven endoscopic bowel biopsies were routine at 67% of centers. AMR was diagnosed at 89% of centers, with plasmapheresis and IVIG being the most common treatments. Variability was noted in desensitization practices and AMR management.CONCLUSIONThis survey highlights considerable consistency in pre- and post-transplant testing and immunosuppressive regimens for IT recipients, while significant variability exists in desensitization strategies and AMR management. Further research is needed to standardize these practices to improve patient outcomes across transplant centers.

01 Mar 2025·Transplant Immunology

Lower basophil count after anti-thymocyte globulin induction is associated with lower incidence of acute cellular rejection in heart transplant recipients

Article

Author: Fabijanović, Dora ; Samardžić, Jure ; Nekić, Andrija ; Skorić, Boško ; Jakuš, Nina ; Došen, Mia Dubravčić ; Planinc, Ivo ; Miličić, Davor ; Čikeš, Maja ; Mjehović, Petra ; Gašparović, Hrvoje

INTRODUCTIONWhile lymphodepletion is considered a therapeutic effect of rabbit anti-thymocyte globulin (rATG), a concomitant decrease in basophil count (BC) has unknown clinical effect.OBJECTIVETo investigate the association between BC following rATG induction and acute cellular rejection (ACR) during the first post-HTx year.METHODSRetrospective single-center study included 183 HTx recipients receiving rATG induction between 2010 and 2021 (mean age 52 ± 13 years, 23 % female). Absolute lymphocyte count (ALC), platelet (PLT) count and BC were assessed on days 0, 7, 14, and 21 following HTx. The primary outcome was the first ACR (grade ≥1B) within the first post-HTx year.RESULTSPatients with ACR had significantly higher BC on day 14 (17/μL (IQR 9-43/μL) vs. 10/μL (IQR 4-19/μL), p = 0.050) and higher PLT on day 7 (143 × 10³/μL (IQR 103-168 × 10³/μL) vs. 105 × 10³/μL (IQR 68-141 × 10³/μL), p = 0.02), with higher ALC on day 14 (308/μL (IQR 171-530/μL) vs. 180/μL (IQR 93-317/μL), p = 0.016) and on day 21 (529/μL (IQR 240-610/μL) vs. 225/μL (IQR 121-328/μL), p < 0.001). In univariate analysis, ACR was associated with higher BC on day 14 (p = 0.004), higher PLT on day 7 (p = 0.02), higher ALC on days 14 (p = 0.04) and 21 (p < 0.001). Multivariable regression model showed the most significant association between higher BC on day 14 and ACR (p = 0.015).CONCLUSIONLower BC two weeks after rATG induction is associated with less ACR during the first post-HTx year.

10

News (Medical) associated with Anti-thymocyte Globulin (Rabbit)

21 Nov 2024

·endpts.com

Samsung Bio's new $668M client; Sanofi expands a factory in France

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of manufacturing deals worth a total of $668 million with an unnamed European pharma client, the CDMO said Tuesday. The deals expire in 2031. Sanofi is investing €40 million ($42.1 million) to expand its bioproduction facility in Lyon, France, the company said Friday. In particular, €25 million ($26.3 million) will be used to make the antibody for Thymoglobulin and €15 million ($15.7 million) to make monoclonal antibodies for type 1 diabetes clinical-stage therapies. The UK regulatory agency MHRA has appointed University of Oxford professor Anthony Harnden as its new chair, according to a Tuesday release. Harnden replaces Stephen Lightfoot, who stepped down in April 2023. LIfT BioSciences has launched a new subsidiary called Eolaíocht Bhitheach LIfT Teoranta, which will operate from Galway, Ireland, the company said Monday. The subsidiary will collaborate with the University of Galway and medical tech manufacturer HookeBio to provide manufacturing and clinical services. Lonza has manufactured its first batch of drug products at its mammalian manufacturing facility in Portsmouth, NH, the company said Wednesday. Convergent Therapeutics has received its first shipment of the radioisotope actinium-225 from Cardinal Health to make its Phase 1/2 prostate cancer radiopharmaceutical, according to a Monday release. Meiji Seika Pharma is investing in the CDMO and mRNA vaccines company Arcalis to improve its supply of mRNA vaccines in Japan, according to a Thursday release. Arcalis will make the API for Meiji’s Covid-19 vaccine. No financial details were disclosed. India-based Unexo Life Sciences was handed an FDA warning letter published Tuesday. It outlined two key issues: failure to produce certain batch record data and dirty air conditioner vents above drug production areas. The White House published a report , dubbed Building a Vibrant Domestic Biomanufacturing Ecosystem, on Friday. It states that the US needs more infrastructure and technology to produce drugs domestically and outlines 11 actions that policymakers should consider to improve manufacturing.

VaccinemRNAExecutive Change

19 Nov 2024

·www.pharmamanufacturing.com

Sanofi invests $42M in Lyon for drug production

Sanofi has announced a €40 million investment in its Lyon Gerland bioproduction site, enhancing its capabilities in immunology-focused drug production. The investment supports the production of Thymoglobulin, used in transplantation, and localizes the manufacturing of TZIELD, a type 1 diabetes treatment, to France. Of the total investment, €25 million will fund the development of a second-generation polyclonal antibody for transplant patients, increasing production capacity and improving environmental sustainability. An additional €15 million will be allocated to producing monoclonal antibodies for type 1 diabetes treatment, previously manufactured outside the EU. Modernization efforts at the Lyon site began in mid-2024, with the first industrial batches of the updated polyclonal antibody expected in 2025 and commercial availability in 2027. Production of the existing treatment continues alongside these upgrades. Similarly, production of the immunomodulatory type 1 diabetes treatment will begin in late 2025, targeting market availability in 2027.

18 Nov 2024

·www.fiercepharma.com

Sanofi lays out €40M to beef up transplant, diabetes drug production in France

Sanofi says its Lyon Gerland site is the sole manufacturer of Thymoglobulin, producing some 1.6 million vials of the treatment for approximately 70,000 patients each year. With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a relatively new Type 1 diabetes drug.Late last week, Sanofi unveiled a 40 million euro ($42.3 million) investment at its Lyon Gerland biomanufacturing site in France.The cash infusion will help cement the site’s immunology pedigree by bolstering local production of the company’s polyclonal antibody Thymoglobulin for kidney transplant rejection as well as provide expected future capacity needs for Type 1 diabetes drug Tzield, Sanofi said in a French language press release.Sanofi got its hands on Tzield, which was first approved by the FDA to delay the progression of Type 1 diabetes, in November 2022 after it completed its $2.9 billion buyout of Provention Bio in early 2023. Of the total investment at Lyon Gerland, 25 million euros are being channeled toward manufacturing and development of a second-generation version of Thymoglobulin, Sanofi explained in its release. The remaining 15 million euro tranche will be used to internalize and localize production of the CD3-directed monoclonal antibody Tzield, the company said.As it stands, Sanofi says its Lyon Gerland site is the sole manufacturer of Thymoglobulin, producing some 1.6 million vials of the treatment for approximately 70,000 patients each year.Following “modernization work” that kicked off this summer, Sanofi has developed a new manufacturing process that it expects to increase production capacity for the immunosuppressant, make supply more reliable and curb the environmental impact of production, according to the release.The first industrial batches using the new process will be rolled out in 2025 with the expectation that the new version of Thymoglobulin will become commercially available in 2027.Apart from Thymoglobulin, Sanofi also plans to develop a new bioproduction zone for Tzield at the Lyon Gerland site. The Type 1 diabetes drug was previously manufactured outside the European Union by a separate company, Sanofi pointed out in its release.Back in January 2023—just a few months before Sanofi’s Provention buyout closed—Provention tapped AGC Biologics for commercial manufacturing of Tzield. Sanofi did not immediately respond to Fierce Pharma’s request for comment on whether that supply pact is still in place.Development of the new bioproduction zone for Tzield will begin in early 2025, with the first product batches expected by the end of next year for marketing in 2027, Sanofi said last week.Sanofi’s latest manufacturing foray in Europe follows several other large investments this year.In May, for instance, Sanofi said it would spend 1 billion euros (then around $1.1 billion) to build a new facility at Vitry-sur-Seine in France to double capacity for monoclonal antibodies, creating 350 new jobs along the way. At the same time, the company said it had earmarked 100 million euros ($108 million) for its Le Trait facility in Normandy, where the French pharma manufactures the anti-inflammatory blockbuster Dupixent.That same month, Sanofi also set aside 10 million euros ($10.8 million) to beef up Tzield production in Lyon Gerland. More recently, Sanofi in August blueprinted a new 1.3 billion euro insulin factory at the company’s campus in Frankfurt Höchst, Germany.With plans to complete the project by 2029, Sanofi has said the plant will eventually house “several hundred” new employees on top of the German campus's existing workforce of more than 4,000.

AcquisitionDrug ApprovalBiosimilar

100 Deals associated with Anti-thymocyte Globulin (Rabbit)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Graft Rejection	Japan	Sanofi KK	22 Apr 2011
Bacterial Infections	Australia	Sanofi-Aventis Australia Pty Ltd.	18 Jul 2008
Graft vs Host Disease	Japan	Sanofi KK	16 Jul 2008
Anemia, Aplastic	South Korea	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993
Cardiac transplant rejection	South Korea	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993
Renal transplant rejection	South Korea	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Death, Sudden, Cardiac	Phase 2	United Kingdom	Genzyme Corp.	01 Jan 2011
Reperfusion Injury	Phase 2	United Kingdom	Genzyme Corp.	01 Jan 2011
Chronic graft-versus-host disease	Phase 2	Canada	Genzyme Corp.	01 Apr 2010
Leukemia	Phase 2	Canada	Genzyme Corp.	01 Apr 2010
Lung transplant rejection	Phase 2	United States	Genzyme Corp.	01 Jan 2006
Primary Graft Dysfunction	Phase 2	United States	Genzyme Corp.	01 Jan 2006
Allograft Rejection	Phase 2	Germany	Genzyme Corp.	01 May 2000
Allograft Rejection	Phase 2	United States	Genzyme Corp.	01 May 2000
Allograft Rejection	Phase 2	United Kingdom	Genzyme Corp.	01 May 2000
Allograft Rejection	Phase 2	Spain	Genzyme Corp.	01 May 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02582775 (CTgov)	Phase 2	Epidermolysis Bullosa	17	Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm B)	(wwmynyzirc) = nwfyczutet kwiuazjfrh (jinhbcfkik, yyksszjkym - axbaegjzub) View more	-	19 Sep 2024
				Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm E)	(wwmynyzirc) = ijijaquapm kwiuazjfrh (jinhbcfkik, tjtrwiyrjt - sgdynabvtz) View more
NCT02441803 (CTgov)	Phase 2	Acute Myeloid Leukemia	11	Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Decitabine+cytarabine+Idarubicin (Matched Sibling Donor Group)	jmfmursfzb(jfusnynxyy) = sqdpbchgfm kdvvsnvcti (fbyeghoxlr, rnazlcfofy - xahmodbjys) View more	-	17 Jan 2024
				Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+cytarabine+Idarubicin (Haploidentical Donor Group)	jmfmursfzb(jfusnynxyy) = iezychsgzv kdvvsnvcti (fbyeghoxlr, ruowgtguzd - unqsvdfnlp) View more
NCT01850108 (CTgov)	Not Applicable	Anemia, Sickle Cell	26	Bone marrow transplantation+Mesna+Fludarabine+Thymoglobulin+Sirolimus+Mycophenolate mofetil (MMF)+Cyclophosphamide (CTX)	(oogaeqjuhi) = vajccnzwsg estrpvckub (antllpfrnj, snpihhzqed - dnppvxwkzd) View more	-	10 Jan 2024
ASH2023	Not Applicable	Hematopoietic stem cell transplantation	8,764	rATG	(fsdnuvcega) = vtzmdosiji mvfxafayvr (uftirucsxa, 15.3 - 17) View more	-	10 Dec 2023
				PTCy	(fsdnuvcega) = mqjnlyrsza mvfxafayvr (uftirucsxa, 10.2 - 14.7) View more
PTCTC ONC1401 (ASH2023)	Not Applicable	Neoplasms	134	rATG	(seaanltqfj) = lqjdjsmdsp dhjxurjvju (osxegggjfw, 50.2 - 67.8) View more	-	10 Dec 2023
ASH2023	Not Applicable	Hematopoietic stem cell transplantation	2,123	rATG	(dzpmpbfudp) = udwirakmyf qjvarswmcs (gxwwznrhcl, 22.7 - 27.3) View more	-	09 Dec 2023
				PTCy	(dzpmpbfudp) = krirvxluid qjvarswmcs (gxwwznrhcl, 14.6 - 21.6) View more
ASH2023	Phase 3	Acute Myeloid Leukemia	6,050	Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil	brkyagnhlc(mwzywzjoau): HR = 1.12 (95% CI, 0.93 - 1.36) View more	-	09 Dec 2023
				Anti-Thymocyte Globulin, tacrolimus or Cyclosporine a and Methotrexate Combinations
NCT04395222 (Phase II study, CTgov)	Phase 2	Primary Graft Dysfunction \| Hematologic Neoplasms \| Graft vs Host Disease	21	Total Body Irradiation+Fludarabine+Anti-thymocyte globulin (rabbit)+Melphalan+tocilizumab (ATG Group I)	ukwtlpmkfk(dcnpmlygqy) = sklnldigtu tchciryocn (subaquovgd, tkqpzxlvce - nifzaqefvg) View more	-	23 Oct 2023
				Total Body Irradiation+Fludarabine+Anti-thymocyte globulin (rabbit)+Melphalan+tocilizumab (ATG Group II)	ukwtlpmkfk(dcnpmlygqy) = fohbcqssoj tchciryocn (subaquovgd, bpfoxcabnb - uhsysbjpzw) View more
NCT04046549 (CTgov)	Phase 2	Allograft Rejection \| Renal transplant rejection	25	VIB4920+Methylprednisolone+Thymoglobulin+Belatacept	wtqdgmzbpl(zoxtalufbw) = zubgazcbma vlzhduylot (yevqkgwbcn, etimdiiffi - uhunzrvcds) View more	-	10 Oct 2023
NCT03096782 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Chronic Lymphocytic Leukemia \| Chronic Myelomonocytic Leukemia \| Acute Biphenotypic Leukemia \| acute leukemia \| Aggressive-Phase Chronic Myelocytic Leukemia \| Refractory Adult Acute Lymphoblastic Leukemia \| Recurrent Hodgkin Lymphoma \| Residual Neoplasm \| Philadelphia chromosome positive chronic myelogenous leukemia \| Histiocytosis, Langerhans-Cell \| Refractory Myelodysplastic Syndrome \| Non-Hodgkin Lymphoma \| Small Lymphocytic Lymphoma	6	Umbilical Cord Blood Transplantation+Filgrastim-sndz+Clofarabine+Fludarabine+Busulfan+cyclophosphamide+Anti-Thymocyte Globulin+Melphalan+Tacrolimus+Mycophenolate Mofetil+Rituximab	zextaomqkn(kyignhhouz) = zidyznngao gjpptprfcj (umbmmqmbat, hzlpzybpdl - pdvuparevt) View more	-	28 Jun 2023

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data